NCT05275439 2026-03-18
Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML
Shattuck Labs, Inc.
Phase 1 Terminated
Clinical Trials
306 trialsNCT03547115 2026-03-17
A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML
MEI Pharma, Inc.
Phase 1 Terminated
NCT03772925 2026-03-03
Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
National Cancer Institute (NCI)
Phase 1 Terminated
NCT04964505 2026-02-23
Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid Leukemia
University of California, Davis
Phase 1 Terminated
NCT03779113 2026-02-18
An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma
Hutchmed
Phase 1 Terminated
NCT05654779 2026-02-11
CLL-1/CD33 Targeted LCAR-AMDR Cells in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Phase 1 Terminated
NCT02381548 2026-01-30
Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 1 Terminated
NCT04764474 2026-01-29
A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH
Hutchmed
Phase 1 Terminated
NCT05787496 2026-01-28
A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms
NextCure, Inc.
Phase 1 Terminated
NCT04230265 2026-01-22
Phase 1 Study of UniCAR02-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies
AvenCell Therapeutics, Inc.
Phase 1 Terminated
NCT04049383 2026-01-12
CAR-20/19-T
Medical College of Wisconsin
Phase 1 Terminated
NCT03760523 2026-01-07
Dose Escalation Study of Minnelide in Relapsed or Refractory Acute Myeloid Leukemia
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Terminated
NCT06018506 2025-11-21
A Phase I Study of BR108 in Hematological Malignancies
BioRay Pharmaceutical Co., Ltd.
Phase 1 Terminated
NCT04937166 2025-11-10
A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies
Kahr Medical
Phase 1 Terminated
NCT03320642 2025-10-21
GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease
Incyte Corporation
Phase 1 Terminated
NCT04678336 2025-10-15
CD123 Redirected T Cells for AML in Pediatric Subjects
University of Pennsylvania
Phase 1 Terminated
NCT03940352 2025-10-10
HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)
Novartis
Phase 1 Terminated
NCT04240704 2025-10-10
Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL
Novartis
Phase 1 Terminated
NCT04702425 2025-10-10
VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)
Novartis
Phase 1 Terminated
NCT05155709 2025-10-10
A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy.
Novartis
Phase 1 Terminated
NCT05168202 2025-09-25
A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes
Bristol-Myers Squibb
Phase 1 Terminated
NCT05961839 2025-09-22
Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Schrödinger, Inc.
Phase 1 Terminated
NCT05712278 2025-09-12
A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia
Sanofi
Phase 1 Terminated
NCT06343376 2025-08-03
Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies
Roswell Park Cancer Institute
Phase 1 Terminated
NCT05817058 2025-07-23
First-in-Human Dose Escalation Study of AFM28 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Affimed GmbH
Phase 1 Terminated
NCT05209152 2025-07-14
AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia
Amgen
Phase 1 Terminated
NCT04789408 2025-07-11
Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia
Gilead Sciences
Phase 1 Terminated
NCT05442580 2025-06-26
CART-38 in Adult AML and MM Patients
University of Pennsylvania
Phase 1 Terminated
NCT02848001 2025-06-12
A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes
Celgene
Phase 1 Terminated
NCT06128044 2025-06-11
AMpLify
Caribou Biosciences, Inc.
Phase 1 Terminated
NCT01751425 2025-06-03
Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT05292898 2025-06-03
A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Phase 1 Terminated
NCT04789655 2025-05-31
Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia
Celgene
Phase 1 Terminated
NCT05038800 2025-05-21
MK-0482-002
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT03400176 2025-05-16
VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib
Novartis
Phase 1 Terminated
NCT03286114 2025-05-11
Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab
University of Michigan Rogel Cancer Center
Phase 1 Terminated
NCT05038644 2025-05-08
XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic Leukemia
Medical College of Wisconsin
Phase 1 Terminated
NCT01352312 2025-04-29
Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma
Thomas Jefferson University
Phase 1 Terminated
NCT03038230 2025-04-06
MCLA-117 in Acute Myelogenous Leukemia
Merus B.V.
Phase 1 Terminated
NCT04553692 2025-03-28
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
IGM Biosciences, Inc.
Phase 1 Terminated
NCT05424380 2025-03-25
A Phase 1, Open Label Study of Intravenous GSK3745417 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Determine RP2D & Schedule in Participants With Relapsed or Refractory Myeloid Malignancies Including AML and HR MDS
GlaxoSmithKline
Phase 1 Terminated
NCT05293912 2025-03-18
SG2501 Safety Study in Subjects with Relapsed or Refractory Hematological Malignancies and Lymphoma.
Hangzhou Sumgen Biotech Co., Ltd.
Phase 1 Terminated
NCT03893682 2025-03-07
A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas
Aptose Biosciences Inc.
Phase 1 Terminated
NCT06068868 2025-03-06
Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
AbbVie
Phase 1 Terminated
NCT05135650 2025-02-13
Pharmacokinetics of Sotrovimab as Pre-exposure Prophylaxis for COVID-19 in Hematopoietic Stem Cell Transplant Recipients, COVIDMAB Study
Fred Hutchinson Cancer Center
Phase 1 Terminated
NCT01743807 2025-01-27
Phase I Study of GNKG168 in Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1 Terminated
NCT04887259 2025-01-27
Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML
Lava Therapeutics
Phase 1 Terminated
NCT04310592 2024-12-12
CYNK001AML01
Celularity Incorporated
Phase 1 Terminated
NCT04526795 2024-12-12
Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT05350163 2024-12-10
T-cell Receptor α/β Depleted Donor Lymphocyte Infusion
Baptist Health South Florida
Phase 1 Terminated